62 related articles for article (PubMed ID: 38568688)
1. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
3. Treatment Access for Gastrointestinal Stromal Tumor in Predominantly Low- and Middle-Income Countries.
Briercheck EL; Wrigglesworth JM; Garcia-Gonzalez I; Scheepers C; Ong MC; Venkatesh V; Stevenson P; Annamalay AA; Coffey DG; Anderson AB; Garcia-Gonzalez P; Wagner MJ
JAMA Netw Open; 2024 Apr; 7(4):e244898. PubMed ID: 38568688
[TBL] [Abstract][Full Text] [Related]
4. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
6. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
[TBL] [Abstract][Full Text] [Related]
7. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
8. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
[TBL] [Abstract][Full Text] [Related]
9. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.
von Mehren M; Kane JM; Riedel RF; Sicklick JK; Pollack SM; Agulnik M; Bui MM; Carr-Ascher J; Choy E; Connelly M; Dry S; Ganjoo KN; Gonzalez RJ; Holder A; Homsi J; Keedy V; Kelly CM; Kim E; Liebner D; McCarter M; McGarry SV; Mesko NW; Meyer C; Pappo AS; Parkes AM; Petersen IA; Poppe M; Schuetze S; Shabason J; Spraker MB; Zimel M; Bergman MA; Sundar H; Hang LE
J Natl Compr Canc Netw; 2022 Nov; 20(11):1204-1214. PubMed ID: 36351335
[TBL] [Abstract][Full Text] [Related]
10. Priorities for cancer research in low- and middle-income countries: a global perspective.
Pramesh CS; Badwe RA; Bhoo-Pathy N; Booth CM; Chinnaswamy G; Dare AJ; de Andrade VP; Hunter DJ; Gopal S; Gospodarowicz M; Gunasekera S; Ilbawi A; Kapambwe S; Kingham P; Kutluk T; Lamichhane N; Mutebi M; Orem J; Parham G; Ranganathan P; Sengar M; Sullivan R; Swaminathan S; Tannock IF; Tomar V; Vanderpuye V; Varghese C; Weiderpass E
Nat Med; 2022 Apr; 28(4):649-657. PubMed ID: 35440716
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Casali PG; Blay JY; Abecassis N; Bajpai J; Bauer S; Biagini R; Bielack S; Bonvalot S; Boukovinas I; Bovee JVMG; Boye K; Brodowicz T; Buonadonna A; De Álava E; Dei Tos AP; Del Muro XG; Dufresne A; Eriksson M; Fedenko A; Ferraresi V; Ferrari A; Frezza AM; Gasperoni S; Gelderblom H; Gouin F; Grignani G; Haas R; Hassan AB; Hindi N; Hohenberger P; Joensuu H; Jones RL; Jungels C; Jutte P; Kasper B; Kawai A; Kopeckova K; Krákorová DA; Le Cesne A; Le Grange F; Legius E; Leithner A; Lopez-Pousa A; Martin-Broto J; Merimsky O; Messiou C; Miah AB; Mir O; Montemurro M; Morosi C; Palmerini E; Pantaleo MA; Piana R; Piperno-Neumann S; Reichardt P; Rutkowski P; Safwat AA; Sangalli C; Sbaraglia M; Scheipl S; Schöffski P; Sleijfer S; Strauss D; Strauss SJ; Hall KS; Trama A; Unk M; van de Sande MAJ; van der Graaf WTA; van Houdt WJ; Frebourg T; Gronchi A; Stacchiotti S;
Ann Oncol; 2022 Jan; 33(1):20-33. PubMed ID: 34560242
[No Abstract] [Full Text] [Related]
12. How to improve access to medical imaging in low- and middle-income countries ?
Frija G; Blažić I; Frush DP; Hierath M; Kawooya M; Donoso-Bach L; Brkljačić B
EClinicalMedicine; 2021 Aug; 38():101034. PubMed ID: 34337368
[TBL] [Abstract][Full Text] [Related]
13. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.
Tan AD; Willemsma K; MacNeill A; DeVries K; Srikanthan A; McGahan C; Hamilton T; Li H; Blanke CD; Simmons CE
Curr Oncol; 2020 Jun; 27(3):e276-e282. PubMed ID: 32669934
[TBL] [Abstract][Full Text] [Related]
15. The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP).
Umeh CA; Garcia-Gonzalez P; Tremblay D; Laing R
EClinicalMedicine; 2020 Feb; 19():100257. PubMed ID: 32140674
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
